Part 4: A new age of drug discovery
Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. These new drugs offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders.
You just have to step into your local chemist to see how far medicine has come over the past 100 years. Life-changing drugs, which were once unthinkable – like antibiotics, insulin and the contraceptive pill - are now commonplace.
But there's still so much we don't know about the medicines we take.
Drug companies are struggling to keep up with the rising demand for new medicines because of the competitive, timely and costly nature of the drug discovery pipeline. In order to deliver new medicines to the people who need them the most, researchers and drug companies need to work together to speed up the process of drug discovery.
By opening up access to newly discovered protein structures and drug targets, Oxford researchers are doing just that.